vs

Side-by-side financial comparison of CITIZENS FINANCIAL SERVICES INC (CZFS) and Phathom Pharmaceuticals, Inc. (PHAT). Click either name above to swap in a different company.

Phathom Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($57.6M vs $29.6M, roughly 1.9× CITIZENS FINANCIAL SERVICES INC). On growth, Phathom Pharmaceuticals, Inc. posted the faster year-over-year revenue change (94.1% vs 13.0%). CITIZENS FINANCIAL SERVICES INC produced more free cash flow last quarter ($35.2M vs $-167.0M).

Citizens Financial Group, Inc. is an American bank holding company, headquartered in Providence, Rhode Island. The company owns the bank Citizens Bank, N.A., which operates in the U.S. states of Connecticut, Delaware, Florida, Maryland, Massachusetts, Michigan, New Hampshire, New Jersey, New York, Ohio, Pennsylvania, Rhode Island, Vermont, and Virginia, as well as Washington, DC.

Phathom Pharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing and commercializing innovative therapies for gastrointestinal diseases. Its lead product candidates address acid-related disorders, inflammatory bowel disease, and other GI conditions, serving patients mainly across North America and Europe.

CZFS vs PHAT — Head-to-Head

Bigger by revenue
PHAT
PHAT
1.9× larger
PHAT
$57.6M
$29.6M
CZFS
Growing faster (revenue YoY)
PHAT
PHAT
+81.2% gap
PHAT
94.1%
13.0%
CZFS
More free cash flow
CZFS
CZFS
$202.2M more FCF
CZFS
$35.2M
$-167.0M
PHAT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CZFS
CZFS
PHAT
PHAT
Revenue
$29.6M
$57.6M
Net Profit
$10.5M
Gross Margin
86.7%
Operating Margin
44.2%
Net Margin
35.4%
Revenue YoY
13.0%
94.1%
Net Profit YoY
31.3%
71.6%
EPS (diluted)
$2.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CZFS
CZFS
PHAT
PHAT
Q4 25
$29.6M
$57.6M
Q3 25
$29.0M
$49.5M
Q2 25
$27.3M
$39.5M
Q1 25
$26.4M
$28.5M
Q4 24
$26.2M
$29.7M
Q3 24
$25.1M
$16.4M
Q2 24
$24.6M
$7.3M
Q1 24
$25.9M
Net Profit
CZFS
CZFS
PHAT
PHAT
Q4 25
$10.5M
Q3 25
$10.0M
$-30.0M
Q2 25
$8.5M
$-75.8M
Q1 25
$7.6M
$-94.3M
Q4 24
$8.0M
Q3 24
$7.5M
$-85.6M
Q2 24
$5.3M
$-91.4M
Q1 24
$7.0M
Gross Margin
CZFS
CZFS
PHAT
PHAT
Q4 25
86.7%
Q3 25
87.5%
Q2 25
87.2%
Q1 25
86.9%
Q4 24
87.1%
Q3 24
85.6%
Q2 24
81.2%
Q1 24
Operating Margin
CZFS
CZFS
PHAT
PHAT
Q4 25
44.2%
Q3 25
42.6%
-30.8%
Q2 25
38.1%
-151.7%
Q1 25
35.5%
-276.5%
Q4 24
37.2%
Q3 24
36.9%
-433.0%
Q2 24
25.9%
-1055.4%
Q1 24
32.8%
Net Margin
CZFS
CZFS
PHAT
PHAT
Q4 25
35.4%
Q3 25
34.5%
-60.5%
Q2 25
31.0%
-191.9%
Q1 25
28.8%
-330.7%
Q4 24
30.5%
Q3 24
30.0%
-523.3%
Q2 24
21.4%
-1248.6%
Q1 24
27.1%
EPS (diluted)
CZFS
CZFS
PHAT
PHAT
Q4 25
$2.17
Q3 25
$2.09
$-0.41
Q2 25
$1.76
$-1.05
Q1 25
$1.60
$-1.31
Q4 24
$1.64
Q3 24
$1.57
$-1.32
Q2 24
$1.10
$-1.56
Q1 24
$1.48

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CZFS
CZFS
PHAT
PHAT
Cash + ST InvestmentsLiquidity on hand
$34.3M
$130.0M
Total DebtLower is stronger
$209.1M
Stockholders' EquityBook value
$338.1M
$-438.2M
Total Assets
$3.1B
$259.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CZFS
CZFS
PHAT
PHAT
Q4 25
$34.3M
$130.0M
Q3 25
$31.1M
$135.2M
Q2 25
$49.5M
$149.6M
Q1 25
$36.8M
$212.3M
Q4 24
$42.2M
$297.3M
Q3 24
$36.8M
$334.7M
Q2 24
$38.4M
$276.2M
Q1 24
$29.6M
Total Debt
CZFS
CZFS
PHAT
PHAT
Q4 25
$209.1M
Q3 25
$207.1M
Q2 25
$205.1M
Q1 25
$203.2M
Q4 24
$201.4M
Q3 24
$175.7M
Q2 24
$174.4M
Q1 24
Stockholders' Equity
CZFS
CZFS
PHAT
PHAT
Q4 25
$338.1M
$-438.2M
Q3 25
$327.7M
$-422.5M
Q2 25
$313.7M
$-405.8M
Q1 25
$308.3M
$-338.4M
Q4 24
$299.7M
$-253.6M
Q3 24
$298.7M
$-187.1M
Q2 24
$286.5M
$-233.8M
Q1 24
$282.7M
Total Assets
CZFS
CZFS
PHAT
PHAT
Q4 25
$3.1B
$259.1M
Q3 25
$3.1B
$240.3M
Q2 25
$3.0B
$250.2M
Q1 25
$3.0B
$294.2M
Q4 24
$3.0B
$378.3M
Q3 24
$3.0B
$387.0M
Q2 24
$2.9B
$319.4M
Q1 24
$2.9B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CZFS
CZFS
PHAT
PHAT
Operating Cash FlowLast quarter
$36.5M
$-166.8M
Free Cash FlowOCF − Capex
$35.2M
$-167.0M
FCF MarginFCF / Revenue
119.0%
-290.0%
Capex IntensityCapex / Revenue
4.4%
0.4%
Cash ConversionOCF / Net Profit
3.49×
TTM Free Cash FlowTrailing 4 quarters
$53.8M
$-328.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CZFS
CZFS
PHAT
PHAT
Q4 25
$36.5M
$-166.8M
Q3 25
$2.9M
$-14.1M
Q2 25
$6.0M
$-62.7M
Q1 25
$10.9M
$-84.9M
Q4 24
$33.2M
$-266.8M
Q3 24
$6.2M
$-63.6M
Q2 24
$3.0M
$-70.7M
Q1 24
$13.5M
Free Cash Flow
CZFS
CZFS
PHAT
PHAT
Q4 25
$35.2M
$-167.0M
Q3 25
$2.7M
$-14.1M
Q2 25
$5.5M
$-62.8M
Q1 25
$10.4M
$-84.9M
Q4 24
$31.9M
$-266.9M
Q3 24
$5.6M
$-63.6M
Q2 24
$2.9M
$-70.8M
Q1 24
$13.4M
FCF Margin
CZFS
CZFS
PHAT
PHAT
Q4 25
119.0%
-290.0%
Q3 25
9.4%
-28.6%
Q2 25
20.1%
-159.0%
Q1 25
39.2%
-297.9%
Q4 24
121.6%
-899.8%
Q3 24
22.3%
-389.0%
Q2 24
11.8%
-966.2%
Q1 24
51.5%
Capex Intensity
CZFS
CZFS
PHAT
PHAT
Q4 25
4.4%
0.4%
Q3 25
0.5%
0.1%
Q2 25
1.8%
0.2%
Q1 25
2.2%
0.1%
Q4 24
5.0%
0.5%
Q3 24
2.5%
0.3%
Q2 24
0.5%
0.6%
Q1 24
0.4%
Cash Conversion
CZFS
CZFS
PHAT
PHAT
Q4 25
3.49×
Q3 25
0.29×
Q2 25
0.71×
Q1 25
1.44×
Q4 24
4.16×
Q3 24
0.83×
Q2 24
0.57×
Q1 24
1.92×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons